AVXL
Price
$8.56
Change
+$0.08 (+0.94%)
Updated
May 8 closing price
Capitalization
728.15M
4 days until earnings call
DNLI
Price
$14.43
Change
+$0.11 (+0.77%)
Updated
May 8 closing price
Capitalization
2.08B
83 days until earnings call
Ad is loading...

AVXL vs DNLI

Header iconAVXL vs DNLI Comparison
Open Charts AVXL vs DNLIBanner chart's image
Anavex Life Sciences
Price$8.56
Change+$0.08 (+0.94%)
Volume$834.67K
Capitalization728.15M
Denali Therapeutics
Price$14.43
Change+$0.11 (+0.77%)
Volume$1.32M
Capitalization2.08B
AVXL vs DNLI Comparison Chart
Loading...
AVXL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVXL vs. DNLI commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVXL is a StrongBuy and DNLI is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (AVXL: $8.56 vs. DNLI: $14.43)
Brand notoriety: AVXL and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVXL: 84% vs. DNLI: 89%
Market capitalization -- AVXL: $728.15M vs. DNLI: $2.08B
AVXL [@Biotechnology] is valued at $728.15M. DNLI’s [@Biotechnology] market capitalization is $2.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVXL’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • AVXL’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, both AVXL and DNLI are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVXL’s TA Score shows that 5 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).

  • AVXL’s TA Score: 5 bullish, 5 bearish.
  • DNLI’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, AVXL is a better buy in the short-term than DNLI.

Price Growth

AVXL (@Biotechnology) experienced а -8.06% price change this week, while DNLI (@Biotechnology) price change was -10.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.66%. For the same industry, the average monthly price growth was +15.23%, and the average quarterly price growth was -12.40%.

Reported Earning Dates

AVXL is expected to report earnings on Aug 12, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-3.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.08B) has a higher market cap than AVXL($728M). AVXL YTD gains are higher at: -20.298 vs. DNLI (-29.195). AVXL has higher annual earnings (EBITDA): -45.2M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. AVXL (121M). AVXL has less debt than DNLI: AVXL (88.2K) vs DNLI (48.7M). AVXL (0) and DNLI (0) have equivalent revenues.
AVXLDNLIAVXL / DNLI
Capitalization728M2.08B35%
EBITDA-45.2M-492.89M9%
Gain YTD-20.298-29.19570%
P/E RatioN/AN/A-
Revenue00-
Total Cash121M832M15%
Total Debt88.2K48.7M0%
FUNDAMENTALS RATINGS
AVXL vs DNLI: Fundamental Ratings
AVXL
DNLI
OUTLOOK RATING
1..100
1024
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
94
Overvalued
PROFIT vs RISK RATING
1..100
78100
SMR RATING
1..100
9339
PRICE GROWTH RATING
1..100
4262
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVXL's Valuation (58) in the Biotechnology industry is somewhat better than the same rating for DNLI (94). This means that AVXL’s stock grew somewhat faster than DNLI’s over the last 12 months.

AVXL's Profit vs Risk Rating (78) in the Biotechnology industry is in the same range as DNLI (100). This means that AVXL’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (39) in the Biotechnology industry is somewhat better than the same rating for AVXL (93). This means that DNLI’s stock grew somewhat faster than AVXL’s over the last 12 months.

AVXL's Price Growth Rating (42) in the Biotechnology industry is in the same range as DNLI (62). This means that AVXL’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as AVXL (100). This means that DNLI’s stock grew similarly to AVXL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVXLDNLI
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 9 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
73%
View a ticker or compare two or three
Ad is loading...
AVXL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FMFAX83.95N/A
N/A
Fidelity Advisor Materials A
RYCHX142.04N/A
N/A
Rydex Technology C
GQHIX13.14N/A
N/A
GQG Partners US Quality Value Fund Ins
HGITX51.28N/A
N/A
Hartford Core Equity R5
USGLX61.61N/A
N/A
JHancock U.S. Global Leaders Growth A

AVXL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVXL has been loosely correlated with PLRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AVXL jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVXL
1D Price
Change %
AVXL100%
+0.94%
PLRX - AVXL
48%
Loosely correlated
N/A
TENX - AVXL
47%
Loosely correlated
+4.45%
RXRX - AVXL
46%
Loosely correlated
+4.77%
AXON - AVXL
45%
Loosely correlated
+14.13%
NTLA - AVXL
42%
Loosely correlated
+13.58%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.77%
BEAM - DNLI
55%
Loosely correlated
+6.32%
ARWR - DNLI
55%
Loosely correlated
+1.45%
ACLX - DNLI
55%
Loosely correlated
+6.27%
RGNX - DNLI
54%
Loosely correlated
-1.24%
NRIX - DNLI
53%
Loosely correlated
+3.66%
More